NBNicole M. Butera

Nicole M. Butera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole M. Butera has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial

    by Richard M. Bergenstal, Jill P. Crandall, Samuel P. Rosin, Nicole M. Butera, Anne Bantle, Cyrus Desouza, Elizabeth Duran-Valdez, Stephanie Hall, William H. Herman, Mary L. Johnson, et al.

    OBJECTIVE: Glycemic management metrics derived from continuous glucose monitoring (CGM) are increasingly recognized as important therapeutic targets. We performed one of the first comparisons of CGM metrics and achievement of CGM targets among four classes of glucose-lowering medications in combination with metformin. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes (GRADE) study randomly assigned participants with type 2 diabetes and taking metformin to add one of four glucose-lowering medications (insulin glargine, glimepiride, liraglutide, or sitagliptin) and followed them for glycemic outcomes for 5 ± 1.3 years. A 2-week masked CGM analysis was conducted midstudy in 1,080 participants to evaluate CGM metrics, 24-h ambulatory glucose profile, and achievement of consensus goals. Treatment effects among the four groups were compared. RESULTS: The sitagliptin and liraglutide groups had the highest time in range 70–180 mg/dL (TIR70–180) and the lowest time below range <70 mg/dL (TBR<70) and percentage coefficient of variation (%CV). The glimepiride group had the lowest TIR70–180, and the highest %CV, TBR<70, and number of CGM-derived hypoglycemic events (P < 0.001), and was the only drug showing daytime hypoglycemia. Sitagliptin and liraglutide were best for achieving consensus goals of very low TBR<54 70% and TBR<70 <4% (P < 0.001). When stratified by HbA1c, mean glucose did not differ among treatments, but %CV and TBR<70 were higher with glargine and glimepiride within each HbA1c stratum. CONCLUSIONS: Incretin class drugs had the lowest %CV, the least hypoglycemia, and best achievement of CGM-based glycemic targets. CGM metrics and profiles provide clinical insights, beyond HbA1c, to guide diabetes management.


  • Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

    by Jeffrey S Gonzalez, Hui Wen, Nicole M Butera, Diane Uschner, Heidi Krause-Steinrauf, Michaela R Gramzinski, Deborah J Wexler, Helen Petrovitch, Claire J Hoogendoorn, Gladys Crespo-Ramos, et al.

    OBJECTIVE: To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: GRADE participants (type 2 diabetes duration 7.5%) glycemic outcomes. RESULTS: Overall mean ± SD adherence (average of participant-level mean ± SD) was high over 3 years of follow-up at 88.7 ± 10.01, on a scale of 0–100, and decreased slightly by 3 years relative to baseline (−2.0 ± 14.7; P < 0.0001). No intergroup differences were observed until 3 years, when adherence was 5% and 3% higher for the glimepiride and sitagliptin groups, respectively, than for liraglutide (both P < 0.05). Over follow-up and across groups, a 10-point decrease in adherence was associated with 15% and 19% increased risk of reaching primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes (both P < 0.0001). Lower adherence was somewhat more predictive of the secondary outcome for those assigned to glargine or liraglutide, compared with glimepiride or sitagliptin (each P < 0.05). No other comparisons were significant. CONCLUSIONS: Medication adherence was consistently high in GRADE. Observed treatment group differences were small and of unclear clinical significance. Overall, lower adherence robustly predicted worsening glycemic control, highlighting the importance of ongoing assessment.


  • Challenges With Access to School Vaccination Surveillance Data to Evaluate the Impact of State-level School Vaccination Exemptions

    by Katrina K. Le, Nicole M. Butera

    Understanding school vaccination rates is critical to controlling disease outbreaks and assessing vaccination policies. Current US surveillance data on school vaccination coverage lack consistency across states, impairing the ability to conduct rigorous analysis on public health policy impacts. This case study describes our experience with publicly available school vaccination surveillance datasets during an attempt to conduct a quasi-experiment on how school vaccination exemption laws affect vaccination coverage. We outline the challenges observed during our attempts to analyze the relationship between policies related to nonmedical school vaccination exemptions and school vaccination coverage in states’ bordering counties. Incomparable data volume, access, granularity, and collection methodology between states were identified as barriers to integrating data across states. Consistent surveillance data collection and reporting over time and among states could lead to improved analysis of public health status, more effective intervention evaluation, and more informed public health decision making.

  • Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort

    by Rodica Pop-Busui, Samuel P Rosin, Nicole M Butera, Heidi Krause-Steinrauf, Hiba Abou Assi, Rajesh K Garg, Silvio E Inzucchi, Aimee Katona, Janet B McGill, Sunder Mudaliar, et al.

    OBJECTIVE: To describe the prevalence and incidence of electrocardiogram (ECG) abnormalities and ECG-derived cardiovascular autonomic neuropathy (CAN) in the GRADE cohort of adults with type 2 diabetes (T2D) <10 years. RESEARCH DESIGN AND METHODS: Individuals with T2D taking metformin alone were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Resting ECGs were completed at the baseline, 2-year, and 4-year study visits and analyzed for minor and major abnormalities and CAN assessed with heart rate variability (HRV) in 4,769 participants. Incidence of new major, minor, and any ECG abnormalities and CAN by treatment group was analyzed using logistic repeated-measures models at years 2 and 4 adjusted for baseline risk factors. RESULTS: At baseline, participants were a mean age of 57.2 ± 10.0 years, 36.3% were women, mean diabetes duration was 4.3 ± 2.8 years, and mean HbA1c was 7.5 ± 0.5%. Participants with ECG abnormalities at baseline (57.1%) and ECG-derived CAN (52.8%) were older and had more severe cardiovascular risk factors. The incidence of minor and major ECG abnormalities was similar among all treatment groups. However, at year 4, major ECG abnormalities were fewer in the liraglutide versus nonliraglutide groups (9% vs. 13%; P = 0.03). The incidence of CAN did not differ between the liraglutide and nonliraglutide groups across visits (P = 0.42); however, one measure of HRV (SD of normal-to-normal R-R intervals) was higher at year 2 in the liraglutide versus nonliraglutide groups (P = 0.02). CONCLUSIONS: ECG abnormalities, including those reflecting CAN, are common in individuals with T2D <10 years and more so in those with certain cardiovascular risk factors. The development of major ECG abnormalities may be lower with liraglutide.


  • Challenges With Access to School Vaccination Surveillance Data to Evaluate the Impact of State-level School Vaccination Exemptions

    by Katrina K. Le, Nicole M. Butera

    Understanding school vaccination rates is critical to controlling disease outbreaks and assessing vaccination policies. Current US surveillance data on school vaccination coverage lack consistency across states, impairing the ability to conduct rigorous analysis on public health policy impacts. This case study describes our experience with publicly available school vaccination surveillance datasets during an attempt to conduct a quasi-experiment on how school vaccination exemption laws affect vaccination coverage. We outline the challenges observed during our attempts to analyze the relationship between policies related to nonmedical school vaccination exemptions and school vaccination coverage in states’ bordering counties. Incomparable data volume, access, granularity, and collection methodology between states were identified as barriers to integrating data across states. Consistent surveillance data collection and reporting over time and among states could lead to improved analysis of public health status, more effective intervention evaluation, and more informed public health decision making.

  • Lack of Association of Emotional Distress With Insulin Initiation in the GRADE Randomized Diabetes Comparative Effectiveness Trial

    by Caroline A. Presley, Nicole M. Butera, Heidi Krause-Steinrauf, Cyrus V. Desouza, Priscilla A. Hollander, Claire J. Hoogendoorn, Violet S. Lagari, Elizabeth A. Legowski, Catherine L. Martin, Neda Rasouli, et al.

    Purpose: The purpose of this study is to evaluate whether higher emotional distress (depressive symptoms or diabetes distress) was associated with a lower likelihood of basal or rapid-acting insulin initiation among participants enrolled in the GRADE Emotional Distress Substudy (EDS). Methods: Individuals with type 2 diabetes 7.5%). Depressive symptoms and diabetes distress were assessed ≤12 months prior to outcome confirmation. Multinomial and binomial logistic regression models examined associations of depressive symptoms and diabetes distress with basal insulin initiation and rapid-acting insulin initiation, respectively. Results: Of the 525 participants expected to start basal insulin, 30.9% initiated ≤6 weeks, 35.2% initiated >6 weeks, and 33.9% never initiated. Of the 325 participants expected to start rapid-acting insulin, 67.4% never initiated. Neither depressive symptoms nor diabetes distress were associated with starting basal or rapid-acting insulin. Conclusions: In the GRADE EDS, approximately one-third of participants did not start basal insulin, and two-thirds of participants did not start rapid-acting insulin. Emotional distress did not appear to play a role in insulin initiation among trial participants.


  • Sociodemographic, Clinical, and Psychosocial Predictors of Short- and Long-term Study Retention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS)

    by Ashley H Tjaden, Barbara H Braffett, Nicole M Butera, Maria Rosario Araneta, Owen Carmichael, Erik J Groessl, Helen P Hazuda, Mary A Hoskin, Uzoma Ibebuogu, Michelle F Magee, et al.

    OBJECTIVE: Success of longitudinal studies depends on retention of participants. We examined characteristics as predictors of retention among participants with prediabetes and type 2 diabetes (T2D) in the Diabetes Prevention Program (DPP) and the follow-up DPP Outcomes Study. RESEARCH DESIGN AND METHODS: A total of 3,234 adults at high risk of T2D joined the DPP (1996–1999, mean age 51 ± 10 years). They were randomized to lifestyle, metformin, or placebo intervention, and then followed through 2020. Logistic regression models estimated the association between baseline sociodemographic, clinical and psychosocial characteristics (life events, family functioning, social support), and short-term retention (∼3 years). Cox proportional hazards models, censoring at death, estimated the association between baseline and time-varying characteristics and time to dropout over the entire 20 years of follow-up. RESULTS: Among surviving participants (n = 3,218), 93% were retained after 3 years, and 75% of those surviving remained engaged over 20 years. Younger age was associated with dropout during DPP and over 20 years of follow-up. Female sex, non-White race and ethnicity, employment, and lack of baseline depressive symptoms were associated with better long-term retention. Over time, better health state (SF-36) (hazard ratio [HR]: 0.89 per 0.1 point; 95% CI: 0.83–0.95) was associated with retention. Greater BMI (HR: 1.06 per 5 kg/m2; 95% CI: 1.00–1.12), more recent life events (HR: 1.08; 95% CI: 1.02–1.14), and depressive symptoms (HR: 1.11 per 5 points; 95% CI: 1.05–1.18) were associated with reduced retention. Among adults 45–59 years of age at baseline, development of T2D was associated with better retention (HR: 0.75; 95% CI: 0.58–0.97). CONCLUSIONS: Twenty-year retention of a racially and geographically diverse cohort with prediabetes is possible. Retention was associated with age, psychosocial factors, T2D development, and BMI.


  • Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

    by Kristina M Utzschneider, Mark Tripputi, Nicole M Butera, Andrea Mari, Samuel P Rosin, Mary Ann Banerji, Richard M Bergenstal, Necole Brown, Anders L Carlson, Ralph A DeFronzo, et al.

    OBJECTIVE: To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell function parameters derived from mathematical modeling of oral glucose tolerance tests were assessed at baseline (N = 4,712) and 1, 3, and 5 years following randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin. Parameters included insulin secretion rate (ISR), glucose sensitivity (insulin response to glucose), rate sensitivity (early insulin response), and potentiation. Linear mixed-effects models were used to compare changes across treatments. With Cox proportional hazards and Classification And Regression Tree (CART) analyses we evaluated associations between model parameters and glycemic failure (A1C >7.5%; 58.5 mmol/mol). RESULTS: β-Cell function parameters increased variably at year 1 across treatments but subsequently declined for all treatments. Statistically significant changes were noted. Liraglutide led to the greatest increases in ISR, glucose sensitivity and potentiation, remaining above baseline at study end. Sitagliptin improved glucose sensitivity, with modest effects on other parameters. Glimepiride temporarily increased ISR and rate sensitivity but minimally increased glucose sensitivity or potentiation. Rate sensitivity increased most with glargine. Higher β-cell function parameters were protective against glycemic deterioration, but treatment did not alter the relationship between these parameters and glycemic outcomes. CONCLUSIONS: Common glucose-lowering medications impact different physiologic components of β-cell function in T2D. Regardless of treatment modality, lower β-cell function associated with early glycemic failure, and β-cell function progressively declined after initial improvement.


  • Open Access

    Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial

    by David M. Nathan, William H. Herman, Mary E. Larkin, Heidi Krause-Steinrauf, Hiba Abou Assi, Andrew J. Ahmann, Janet Brown-Friday, Daniel S. Hsia, Tasma Harindhanavudhi, Mary Johnson, et al.

    OBJECTIVE: To determine whether the relationship between average glucose (AG) levels and hemoglobin A1c (HbA1c) differs across racial/ethnic groups. RESEARCH DESIGN AND METHODS: We performed a prospective substudy of GRADE, a comparative effectiveness randomized trial conducted in 36 centers in the U.S. A total of 1,454 of the 5,047 participants in the GRADE cohort, including 534 non-Hispanic White (NHW), 389 non-Hispanic Black (NHB), and 327 Hispanic White patients and 204 patients of other racial/ethnic backgrounds, were included in the substudy. Continuous glucose monitoring (CGM) performed for 10 days was used to calculate AG10. Immediately after CGM, HbA1c and glycated albumin were measured. Fasting plasma glucose (FPG) and glucose area under the curve (AUC) were derived from a 75-g oral glucose tolerance test. RESULTS: The relationship between AG10 and HbA1c was significantly different for NHB compared with NHW patients and those of other racial/ethnic groups. HbA1c levels were 0.2–0.6 percentage points higher in NHB than in NHW patients for AG10 levels from 100 to 250 mg/dL. For an HbA1c of 7%, AG10 was 11 mg/dL higher for NHW than for NHB patients. Similar findings were observed across races for relationships of FPG and AUC with HbA1c and for glucose measurements with glycated albumin levels. Differences in the relationship between AG10 and HbA1c across racial groups remained after adjustments for any demographic or other differences between racial/ethnic subgroups. CONCLUSIONS: The relationship between several measures of glucose with HbA1c and glycated albumin consistently differed across races. These findings should be considered in setting treatment goals and diagnostic levels.


  • Open Access

    Polyvictimization and Adolescent Health and Well-Being in Ethiopia: The Mediating Role of Resilience

    by Lior Miller, Nicole M. Butera, Mary Ellsberg, Sarah Baird

    Interpersonal violence is a pervasive experience affecting one billion children and adolescents annually, resulting in adverse health and well-being outcomes. Evidence suggests that polyvictimization, the experience of multiple forms of violence, is associated with more harmful consequences for adolescents than experiencing individual types of violence, although data from low-and middle-income countries are limited. This study analyzed data on over 4100 adolescents from the Gender and Adolescence, Global Evidence Study in Ethiopia to examine the association between polyvictimization and adolescent mental and physical health and the mediating role of resilience using linear regression and path analysis. We hypothesized that adolescents experiencing polyvictimization would experience worse mental and physical health than those experiencing no types or individual types of victimization, and that resilience would mediate these relationships. Half of sampled girls and over half of boys experienced polyvictimization. Among both sexes, polyvictimization was associated with worse mental but not worse physical health. Resilience mediated the association between polyvictimization and mental health among girls only. Strengthening resilience among girls may be an effective avenue for mitigating polyvictimization’s negative mental health effects, but additional research and programming for preventing and identifying polyvictimized adolescents and linking them to care is needed.